DK1154792T3 - Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans - Google Patents

Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans

Info

Publication number
DK1154792T3
DK1154792T3 DK00906305T DK00906305T DK1154792T3 DK 1154792 T3 DK1154792 T3 DK 1154792T3 DK 00906305 T DK00906305 T DK 00906305T DK 00906305 T DK00906305 T DK 00906305T DK 1154792 T3 DK1154792 T3 DK 1154792T3
Authority
DK
Denmark
Prior art keywords
sub
adjuvant
fatty acids
monoglycerides
vaccine formulation
Prior art date
Application number
DK00906305T
Other languages
English (en)
Inventor
Ulf Schroeder
Stefan Svenson
Original Assignee
Eurocine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Ab filed Critical Eurocine Ab
Application granted granted Critical
Publication of DK1154792T3 publication Critical patent/DK1154792T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00906305T 1999-02-12 2000-02-09 Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans DK1154792T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition
PCT/EP2000/001046 WO2000047225A2 (en) 1999-02-12 2000-02-09 Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant

Publications (1)

Publication Number Publication Date
DK1154792T3 true DK1154792T3 (da) 2007-02-12

Family

ID=20414469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00906305T DK1154792T3 (da) 1999-02-12 2000-02-09 Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans

Country Status (10)

Country Link
US (1) US6936260B1 (da)
EP (1) EP1154792B1 (da)
AT (1) ATE342065T1 (da)
AU (1) AU769390B2 (da)
DE (1) DE60031243T2 (da)
DK (1) DK1154792T3 (da)
ES (1) ES2275495T3 (da)
NZ (1) NZ513130A (da)
SE (1) SE9900495D0 (da)
WO (1) WO2000047225A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
AU2002364952B2 (en) * 2001-11-14 2008-04-10 Novavax, Inc. Mycobacterial vaccine
NZ555055A (en) * 2001-12-11 2010-06-25 Pasteur Institut Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
CU23476A1 (es) * 2004-01-29 2009-12-17 Ct Ingenieria Genetica Biotech Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
ATE531389T1 (de) * 2005-01-28 2011-11-15 Univ Northwest Lipid- und distickstoffoxidverbindung als hilfsmittel zur erhöhung der impfstoffeffizienz
EP2144626B8 (en) * 2007-04-12 2015-02-18 Mico Bio, Inc. Tuberculosis vaccine and method of using same
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
AU2012245475A1 (en) * 2011-04-20 2013-11-28 Mico Bio, Inc. Composition and method for enhancing an immune response
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1993006921A1 (en) * 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
IL126314A (en) * 1996-03-25 2003-07-31 Northwest Biotherapeutics Inc Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering

Also Published As

Publication number Publication date
DE60031243T2 (de) 2007-05-24
DE60031243D1 (de) 2006-11-23
EP1154792B1 (en) 2006-10-11
EP1154792A2 (en) 2001-11-21
WO2000047225A3 (en) 2000-12-14
ES2275495T3 (es) 2007-06-16
AU769390B2 (en) 2004-01-22
SE9900495D0 (sv) 1999-02-12
AU2803500A (en) 2000-08-29
US6936260B1 (en) 2005-08-30
WO2000047225A2 (en) 2000-08-17
ATE342065T1 (de) 2006-11-15
NZ513130A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
DK0777490T3 (da) Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
NO20002741L (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
DK1154792T3 (da) Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
NO20052010L (no) Immunogen sammensetning
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
NO976060L (no) Vaksiner mot hepatitt C
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
BR9910296A (pt) Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
DK0652773T3 (da) Anvendelse af nor- og homo-galdesyrederivater somabsorptionsfremmende bestanddele i lægemidler
EP2283858A3 (en) West Nile Vaccine
DE69634024D1 (de) Adjuvans für vitale Impfstoffe
DK0745388T3 (da) Mammalt vaccinepræparat omfattende squalen eller squalan, phospholipid og et overfladeaktivt stof som adjuvans
CO5560550A2 (es) Producto en combinaciones de derivados de 1,4-benzotiepina- 1-1-dioxido con otros ingredientes activos, y su uso
GB9306731D0 (en) Vaccines
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
SE9602280D0 (sv) Immunstimulerande lipidformulering
DK1150713T3 (da) Vaccineformulering der omfatter monoglycerider eller fedtsyrer som adjuvans
GB9422990D0 (en) Immunogenic compositions
BR0008949A (pt) Composições de lipoglicano e métodos de tratamento de infecções parasitárias
BR9713296A (pt) Processo para a preparação de derivados 2-amino-2-imidazolino, guanidino, e 2-amino-3,4,5,6-tetrahidro-pirimidina
ES2145541T3 (es) Nuevos seco-d-esteroides activos sobre el sistema cardiovascular, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.